International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 04 Issue 10 October 2024

Page No: 1855-1861

DOI: https://doi.org/10.47191/ijmscrs/v4-i10-23, Impact Factor: 7.949

Comprehensive Review of Shone's Syndrome: Pathophysiology, Clinical Manifestations, and Management Strategies

Donaldo Emiliano Silva López[1], Pedro Luis Matus Rojo[2], Erick Adolfo Meza Soto[3], Juan Basilio Vargas Alfaro[3], Laura Lilia Robledo Silva[4], Metzly Aztrid Pérez León[5]

[1]Tecnológico de Monterrey Campus Monterrey, Nuevo Léon, Mexico.

[2]Universidad Autónoma de Sinaloa. Mexico

[3]Hospital General de Los Mochis, Jesús Kumate Rodríguez. Secretaria de salud. Sinaloa, México.

[4]Universidad Autónoma de Guadalajara. Zapopan, Jalisco, México.

[5]Universidad autónoma de Durango campus Culiacán. Culiacán, Sinaloa, Mexico.

ABSTRACT

Shone's syndrome, a rare congenital heart disease, encompasses a complex array of obstructive lesions within the left heart. First described in 1963, this syndrome typically presents with a combination of supravalvular mitral ring, parachute mitral valve, subaortic stenosis, and coarctation of the aorta. The intricate nature of these anomalies presents significant diagnostic and therapeutic challenges. This review aims to elucidate the pathophysiological mechanisms underlying Shone's syndrome, provide a detailed account of its clinical manifestations, and discuss current management strategies, including surgical and medical interventions. Through an in-depth analysis of existing literature, we seek to enhance understanding and improve outcomes for patients afflicted with this multifaceted condition.

KEYWORDS: Shone, syndrome, heart

ARTICLE DETAILS

Published On:
14 October 2024

Available on:
https://ijmscr.org/

INTRODUCTION

Shone's syndrome, a rare but critical congenital heart defect, was initially delineated by Dr. John D. Shone in 1963. It is characterized by a quartet of obstructive lesions affecting the left side of the heart: supravalvular mitral ring, parachute mitral valve, subaortic stenosis, and coarctation of the aorta. These anomalies disrupt normal cardiac function and hemodynamics, often leading to significant morbidity and necessitating early intervention.1,2

The supravalvular mitral ring constitutes a fibrous or membranous structure located above the mitral valve, impeding mitral inflow. The parachute mitral valve, characterized by all chordae tendineae attaching to a single papillary muscle, results in restricted valve motion and functional mitral stenosis. Subaortic stenosis, typically involving a fibromuscular or membranous obstruction below the aortic valve, compromises left ventricular outflow. Coarctation of the aorta, a narrowing of the aortic lumen, further exacerbates the left ventricular workload and systemic hypertension.2,3

The clinical presentation of Shone's syndrome varies, ranging from asymptomatic cases detected incidentally to severe manifestations such as heart failure, pulmonary hypertension, and growth retardation in infants and children. Diagnostic modalities, including echocardiography, cardiac MRI, and cardiac catheterization, are pivotal in delineating the extent and severity of the lesions.3,4

Management of Shone's syndrome is multifaceted, often requiring a combination of surgical and medical approaches. Surgical correction of the obstructive lesions is typically undertaken in a staged manner, addressing the most hemodynamically significant anomalies first. Medical management focuses on optimizing cardiac function, controlling symptoms, and preventing complications.4,5

Despite advancements in diagnostic and therapeutic techniques, Shone's syndrome remains a formidable challenge due to the complexity of the lesions and the variability in clinical presentation. This review aims to provide a comprehensive overview of Shone's syndrome, emphasizing the pathophysiology, clinical features, and

contemporary management strategies. By enhancing our understanding of this rare condition, we hope to improve diagnostic accuracy, therapeutic outcomes, and overall prognosis for affected individuals.4,5

Epidemiology

Shone's syndrome, a rare congenital cardiovascular anomaly, presents a significant challenge in pediatric cardiology due to its multifaceted nature and relatively low incidence. Epidemiological data on Shone's syndrome are sparse, largely due to the rarity of the condition and the complexity of its diagnosis. However, available literature and clinical reports provide some insights into its occurrence, demographic distribution, and associated risk factors.4,5

Incidence and Prevalence

Shone's syndrome is estimated to occur in approximately 0.6 to 1.2 per 10,000 live births. The exact prevalence is difficult to ascertain due to the variability in the presentation and severity of the condition. It is important to note that Shone's syndrome can often be underdiagnosed or misdiagnosed, especially in less severe cases where the full spectrum of the characteristic obstructive lesions may not be immediately evident.4,5

Demographic Distribution

The demographic distribution of Shone's syndrome does not exhibit significant gender predilection; both males and females are affected with similar frequency. There is no substantial evidence to suggest a racial or ethnic predilection, as cases have been reported across various populations globally. However, some studies suggest a slightly higher prevalence in populations with a higher incidence of congenital heart defects, potentially due to genetic and environmental factors.4,5

Age of Diagnosis

The age at which Shone's syndrome is diagnosed can vary widely, ranging from the neonatal period to late childhood. In severe cases, infants may present with symptoms shortly after birth, including respiratory distress, feeding difficulties, and failure to thrive, prompting early diagnostic investigations. Conversely, milder cases may go undetected until later in childhood when symptoms such as exercise intolerance, recurrent respiratory infections, or heart murmurs lead to further evaluation.4,5

Associated Congenital Heart Defects

Shone's syndrome is often associated with other congenital heart defects, which can complicate its clinical presentation and management. Commonly associated anomalies include ventricular septal defects (VSDs), atrial septal defects (ASDs), bicuspid aortic valve, and patent ductus arteriosus (PDA). The presence of these additional defects can influence the clinical course and prognosis of patients with Shone's syndrome.6,7

Genetic and Environmental Factors

The etiology of Shone's syndrome is not well understood, but it is believed to result from disruptions in normal cardiac development during embryogenesis. While most cases appear sporadic, there are reports of familial occurrences suggesting a potential genetic component. Mutations in genes involved in cardiac morphogenesis and function, such as those affecting the NOTCH signaling pathway, have been implicated in congenital heart defects, though specific genetic links to Shone's syndrome remain to be conclusively identified.6,7

Environmental factors, including maternal health conditions (e.g., diabetes, obesity) and exposures to teratogens during pregnancy, have been associated with an increased risk of congenital heart defects. However, their specific role in the pathogenesis of Shone's syndrome requires further investigation.6,7

Prognosis and Survival

The prognosis of Shone's syndrome varies depending on the severity and number of obstructive lesions, the presence of associated cardiac anomalies, and the timing and success of surgical interventions. Advances in surgical techniques and perioperative care have significantly improved outcomes, with many patients surviving into adulthood. However, long-term follow-up is essential, as individuals with Shone's syndrome may be at risk for residual or recurrent obstruction, ventricular dysfunction, and other complications.6,7

Shone's syndrome is a rare and complex congenital heart disease with a diverse epidemiological profile. While significant progress has been made in understanding and managing this condition, ongoing research and clinical vigilance are crucial to improving diagnosis, treatment, and long-term outcomes for affected individuals.6,7

Clinical Manifestations

Shone's syndrome, characterized by a combination of left-sided obstructive cardiac lesions, presents a wide spectrum of clinical manifestations. These manifestations can vary significantly depending on the severity and combination of the lesions, as well as the presence of associated congenital heart defects. Understanding the clinical presentation is crucial for timely diagnosis and appropriate management.6,7

Supravalvular Mitral Ring

The supravalvular mitral ring is a fibrous or membranous structure located above the mitral valve, leading to mitral inflow obstruction. Clinically, this can manifest as:

Heart Murmurs:

A systolic murmur due to turbulent flow across the mitral valve.

Symptoms of Mitral Stenosis: Patients may present with exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and fatigue. In severe cases, pulmonary edema can occur.

Left Atrial Enlargement: Chronic obstruction can lead to left atrial enlargement, detectable on imaging studies such as echocardiography.6,7

Parachute Mitral Valve

In the parachute mitral valve, all chordae tendineae are attached to a single papillary muscle, resulting in restricted valve motion and functional mitral stenosis. 6,7,8

Clinical manifestations include:

Heart Murmurs

A characteristic murmur similar to that heard in mitral stenosis.

Reduced Cardiac Output: Due to impaired mitral valve function, leading to symptoms such as fatigue, poor growth in infants, and exercise intolerance in older children.8,9

Pulmonary Hypertension: Chronic elevation of left atrial pressure can lead to pulmonary hypertension, presenting with signs of right heart failure in advanced cases.8,9

Subaortic Stenosis

Subaortic stenosis, typically a fibromuscular or membranous obstruction below the aortic valve, impedes left ventricular outflow. Clinical features include:8,9

Heart Murmurs:

A harsh, systolic ejection murmur heard best at the right upper sternal border.

Left Ventricular Hypertrophy: Chronic pressure overload leads to left ventricular hypertrophy, which can be seen on echocardiography and electrocardiography (ECG).8,9

Syncope and Angina: Severe obstruction can result in decreased cardiac output during exertion, leading to syncope or anginal chest pain.8,9

Coarctation of the Aorta

Coarctation of the aorta involves a narrowing of the aortic lumen, usually just distal to the left subclavian artery. This leads to increased afterload and systemic hypertension. Clinical manifestations include:

Hypertension: Elevated blood pressure, particularly in the upper extremities, with diminished or absent femoral pulses.8,9

Heart Murmurs: A systolic murmur, often accompanied by a continuous murmur if collateral vessels are present.8,9

Heart Failure: In severe cases, infants may present with signs of heart failure, including tachypnea, poor feeding, and failure to thrive.8,9

Differential Cyanosis: In cases where coarctation is associated with a patent ductus arteriosus (PDA), lower extremity cyanosis can be observed.8,9

Combined Lesions

The combined presence of these lesions in Shone's syndrome results in a complex clinical picture:8,9

Heart Failure: The interplay of multiple obstructive lesions often leads to congestive heart failure. Signs include tachypnea, hepatomegaly, poor feeding, and failure to thrive in infants, and exercise intolerance in older children.8,9

Growth Retardation: Chronic heart failure and reduced cardiac output can result in poor growth and developmental delay.8,9

Recurrent Respiratory Infections: Pulmonary congestion and heart failure predispose patients to frequent respiratory infections.8,9

Cardiomegaly: Imaging studies typically reveal an enlarged heart due to hypertrophy and dilation resulting from chronic pressure and volume overload.8,9

Diagnostic Clues

Several diagnostic clues can aid in the recognition of Shone's syndrome:

Physical Examination: Detailed auscultation may reveal multiple murmurs corresponding to different obstructive lesions. Differential blood pressure measurements between the upper and lower extremities can indicate coarctation of the aorta.8,9

Imaging Studies: Echocardiography is the cornerstone of diagnosis, providing detailed visualization of the mitral valve apparatus, left ventricular outflow tract, and aortic arch. Cardiac MRI and CT angiography offer additional anatomical details and can assess the severity of coarctation.8,9

Electrocardiography: ECG findings may include left atrial enlargement, left ventricular hypertrophy, and signs of pulmonary hypertension.8,9

In conclusion, the clinical manifestations of Shone's syndrome are diverse and complex, reflecting the interplay of multiple left-sided obstructive lesions. A high index of suspicion and comprehensive diagnostic evaluation are essential for timely identification and appropriate management of this challenging congenital heart condition.8,9

Diagnosis of Shone's Syndrome

Shone's syndrome, a rare congenital heart disease comprising multiple left-sided obstructive lesions, presents a unique diagnostic challenge due to its heterogeneous and complex nature. Accurate and timely diagnosis is critical for effective management and improved outcomes. This section outlines the diagnostic approach, including clinical evaluation, imaging modalities, and differential diagnosis considerations, for Shone's syndrome.10,11

Clinical Evaluation

History and Physical Examination:

The initial step in diagnosing Shone's syndrome involves a thorough clinical history and physical examination. Key aspects include:

History: Careful inquiry about symptoms such as dyspnea, fatigue, poor feeding, growth retardation, and exercise intolerance. Family history of congenital heart disease should also be noted.10,11

Physical Examination: Auscultation may reveal multiple heart murmurs, each corresponding to different obstructive lesions. Notable findings include:

A systolic murmur at the apex due to mitral stenosis (supravalvular mitral ring or parachute mitral valve).10,11

A harsh systolic ejection murmur at the right upper sternal border indicative of subaortic stenosis.10,11

A systolic murmur over the back or left infraclavicular area due to coarctation of the aorta.

Differential blood pressure measurements between the upper and lower extremities, with higher pressures in the arms than in the legs, suggestive of coarctation.10,11

Signs of heart failure, such as tachypnea, hepatomegaly, and peripheral edema.

Laboratory Tests:

While not specific for Shone's syndrome, laboratory tests can help evaluate the overall health status and identify complications:10,11

B-type Natriuretic Peptide (BNP): Elevated levels may indicate heart failure.

Complete Blood Count (CBC): Anemia or polycythemia may be present, especially in cyanotic cases.10,11

Serum Electrolytes and Renal Function Tests: To assess end-organ effects of heart failure.

Imaging Modalities

Echocardiography:

Echocardiography is the cornerstone of diagnosis for Shone's syndrome. It provides detailed information on cardiac anatomy and function, and identifies the characteristic obstructive lesions:10,11

Supravalvular Mitral Ring: Appears as an echogenic ring above the mitral valve, causing mitral inflow obstruction.10,11

Parachute Mitral Valve: Shows all chordae tendineae attaching to a single papillary muscle, leading to restricted mitral valve motion.10,11

Subaortic Stenosis: Demonstrates a fibromuscular or membranous obstruction below the aortic valve, with associated left ventricular hypertrophy.10,11

Coarctation of the Aorta: Visualizes the narrowing of the aortic lumen, often just distal to the left subclavian artery. Doppler echocardiography can assess the gradient across the coarctation.

Cardiac MRI and CT Angiography:

These advanced imaging techniques provide additional anatomical details and are particularly useful when echocardiographic images are suboptimal:

Cardiac MRI: Offers high-resolution images of the heart and great vessels, enabling precise assessment of the obstructive lesions and associated anomalies. It is particularly valuable in evaluating complex cases and planning surgical interventions.10,11

CT Angiography: Provides detailed visualization of the aortic arch and coarctation, and can be used to assess the severity and extent of the obstruction. It is also useful for preoperative planning and postoperative evaluation.10,11

Cardiac Catheterization:

Cardiac catheterization is typically reserved for cases where non-invasive imaging is inconclusive or when interventional procedures are planned:

Hemodynamic Assessment: Measures pressures within the heart chambers and across obstructive lesions, providing precise information on the severity of stenosis.

Angiography: Visualizes the coronary arteries, aorta, and other major vessels, helping to delineate the anatomical details of the obstructive lesions.10,11

Differential Diagnosis

The differential diagnosis of Shone's syndrome includes other congenital and acquired conditions that cause similar clinical and imaging findings:

Isolated Left-Sided Obstructive Lesions: Conditions such as isolated coarctation of the aorta, isolated subaortic stenosis, or isolated mitral stenosis.10,11

Hypoplastic Left Heart Syndrome (HLHS): Characterized by underdevelopment of left-sided heart structures, presenting with severe heart failure and cyanosis in neonates.

Cor Triatriatum: A rare congenital anomaly where a membrane divides the left atrium, causing obstruction of blood flow and mimicking mitral stenosis.10,11

Rheumatic Heart Disease: Acquired mitral stenosis secondary to rheumatic fever, though rare in developed countries, should be considered in differential diagnosis.10,11

Genetic Testing

Given the potential genetic basis of congenital heart defects, genetic testing may be considered, especially in cases with a family history of congenital heart disease. Identification of specific genetic mutations or syndromes associated with Shone's syndrome can aid in understanding the etiology and guiding management.10,11

The diagnosis of Shone's syndrome requires a multidisciplinary approach, integrating clinical evaluation, advanced imaging techniques, and consideration of differential diagnoses. Accurate and timely diagnosis is essential for effective management and improving the prognosis of patients with this complex congenital heart condition.10,11

Treatment of Shone's Syndrome

The treatment of Shone's syndrome is a multifaceted and often staged approach, given the complexity and variety of obstructive lesions that characterize this rare congenital heart disease. The primary goal is to alleviate obstructions to ensure adequate blood flow, improve cardiac function, and manage symptoms effectively. Treatment strategies typically

involve a combination of surgical interventions, catheter-based procedures, and medical management tailored to the individual patient's condition.10,11

Surgical Interventions

Surgical correction is the cornerstone of treatment for Shone's syndrome. Due to the multiple left-sided obstructive lesions, a staged approach is often required, addressing the most hemodynamically significant obstructions first.10,11

Supravalvular Mitral Ring:

Resection of the Ring: The surgical removal of the supravalvular mitral ring is performed to relieve the obstruction to mitral inflow. This procedure requires careful dissection to avoid damage to the mitral valve apparatus and ensure complete removal of the ring.

Parachute Mitral Valve:

Mitral Valve Repair: Surgical repair of the parachute mitral valve aims to separate the chordae tendineae and improve valve mobility. Techniques include chordal splitting and papillary muscle splitting to distribute the tension evenly across the valve.10,11

Mitral Valve Replacement: In severe cases where repair is not feasible or effective, mitral valve replacement may be necessary. Prosthetic valve selection (mechanical or bioprosthetic) depends on the patient's age, growth potential, and risk factors for thromboembolism.10,11

Subaortic Stenosis:

Resection of the Obstruction: Subaortic stenosis is typically managed by surgical resection of the fibromuscular or membranous obstruction (myectomy or membranectomy). This procedure aims to relieve left ventricular outflow tract obstruction and reduce left ventricular pressure overload.10,11

Ross-Konno Procedure: In cases with extensive subaortic stenosis and aortic valve involvement, the Ross-Konno procedure may be performed. This involves replacing the aortic valve with the patient's pulmonary valve and enlarging the left ventricular outflow tract.10,11

Coarctation of the Aorta:

End-to-End Anastomosis:

Surgical correction of coarctation of the aorta often involves resection of the narrowed segment and end-to-end anastomosis, restoring normal aortic continuity.10,11

Subclavian Flap Aortoplasty: This technique uses the left subclavian artery to enlarge the aortic lumen, particularly useful in infants and young children.10,11

Patch Aortoplasty: A synthetic or autologous patch is used to widen the narrowed segment of the aorta.12,13

Interposition Graft: In severe cases, a synthetic graft may be used to replace the narrowed section of the aorta.12,13

Catheter-Based Interventions

Catheter-based interventions provide a less invasive alternative to surgery and can be particularly useful in certain cases or as a bridge to surgical repair.12,13

Balloon Angioplasty:

Coarctation of the Aorta: Balloon angioplasty can be used to dilate the narrowed segment of the aorta. This procedure is often followed by stent placement to maintain patency and reduce the risk of re-coarctation.12,13

Subaortic Stenosis: Balloon angioplasty may be attempted in subaortic stenosis, although surgical resection remains the preferred treatment for more severe cases.12,13

Stent Placement:

Coarctation Stenting: In older children and adults, stent placement can provide durable relief of coarctation. Covered stents are preferred in cases with associated aneurysms to prevent complications.12,13

Medical Management

Medical management is essential in optimizing cardiac function, controlling symptoms, and managing complications. It often serves as an adjunct to surgical and catheter-based interventions.12,13

Heart Failure Management:

Diuretics: Diuretics such as furosemide are used to manage fluid overload and reduce symptoms of heart failure.12,13

ACE Inhibitors/ARBs: These agents help reduce afterload and improve cardiac output by dilating blood vessels.12,13

Beta-Blockers: Used to manage heart failure and control hypertension, particularly in patients with left ventricular hypertrophy and outflow tract obstruction.12,13

Anticoagulation:

Post-Surgical Anticoagulation: Patients undergoing mitral valve replacement, especially with mechanical prostheses, require long-term anticoagulation to prevent thromboembolic complications.12,13

Aspirin or Warfarin: Choice of anticoagulant depends on the type of valve replacement and individual risk factors.

Hypertension Management:

Antihypertensive Therapy: Effective blood pressure control is crucial, particularly in patients with coarctation of the aorta. A combination of antihypertensive agents, including beta-blockers, ACE inhibitors, or calcium channel blockers, may be necessary.12,13

Prophylaxis Against Infective Endocarditis:

Antibiotic Prophylaxis: Given the risk of infective endocarditis in patients with congenital heart defects, antibiotic prophylaxis is recommended for dental procedures and other invasive interventions.12,13

Long-Term Follow-Up and Monitoring

Patients with Shone's syndrome require lifelong follow-up to monitor for recurrence of obstructions, progression of

residual lesions, and development of new complications. Regular follow-up includes:

Echocardiography: Routine imaging to assess cardiac function, valve performance, and any residual or recurrent obstructions.14,15

Cardiac MRI/CT: Advanced imaging for detailed evaluation of complex anatomy and postoperative changes.

Exercise Testing: To assess functional capacity and detect exercise-induced symptoms or hemodynamic changes.14,15

CONCLUSION

The treatment of Shone's syndrome is complex and requires a multidisciplinary approach involving pediatric cardiologists, cardiothoracic surgeons, and interventional cardiologists. Tailored treatment strategies, combining surgical, catheter-based, and medical therapies, are essential to address the unique challenges posed by this rare congenital heart disease. Ongoing advancements in surgical techniques, interventional procedures, and medical management continue to improve outcomes for patients with Shone's syndrome, emphasizing the importance of comprehensive and coordinated care.

Shone's syndrome represents a unique and complex congenital heart disease, characterized by the presence of multiple left-sided obstructive lesions including supravalvular mitral ring, parachute mitral valve, subaortic stenosis, and coarctation of the aorta. Each of these anomalies contributes to significant hemodynamic disturbances, presenting considerable challenges in both diagnosis and management. The intricacies of Shone's syndrome necessitate a comprehensive understanding of its pathophysiology, clinical manifestations, and therapeutic strategies to optimize patient outcomes.

Pathophysiological Insights

The pathophysiological complexity of Shone's syndrome lies in the interplay between the obstructive lesions, each contributing to an increase in left atrial and left ventricular pressures, leading to hypertrophy, dilation, and ultimately heart failure if left untreated. The supravalvular mitral ring and parachute mitral valve impede mitral inflow, causing elevated left atrial pressures and pulmonary congestion. Subaortic stenosis further exacerbates left ventricular outflow obstruction, resulting in left ventricular hypertrophy and increased myocardial oxygen demand. Coarctation of the aorta adds an additional layer of complexity by imposing increased afterload on the left ventricle and potentially leading to systemic hypertension and its associated complications.

Clinical Implications

Clinically, Shone's syndrome presents with a spectrum of manifestations that vary with the severity and combination of obstructive lesions. From subtle heart murmurs detected in routine examinations to severe heart failure symptoms in infants, the clinical presentation requires a high index of suspicion and meticulous evaluation. The diagnostic process is significantly bolstered by advanced imaging modalities such as echocardiography, cardiac MRI, and CT angiography, which provide detailed anatomical and functional insights. Cardiac catheterization remains a critical tool for hemodynamic assessment and therapeutic planning.

Therapeutic Strategies

The management of Shone's syndrome is inherently complex and typically involves a staged surgical approach to address each obstructive lesion. Early and precise surgical intervention is crucial to alleviate obstructions, reduce pressure overload, and improve cardiac function. Techniques such as resection of the supravalvular mitral ring, mitral valve repair or replacement, subaortic stenosis resection, and various surgical methods for coarctation repair, including end-to-end anastomosis and stent placement, are pivotal in the comprehensive treatment plan.

Catheter-based interventions, particularly balloon angioplasty and stent placement, provide minimally invasive options that can serve as either primary treatments or adjuncts to surgery. These procedures offer the advantages of reduced recovery times and the potential for repeat interventions as the patient grows.

Medical management plays a supportive role, focusing on heart failure management, hypertension control, and prevention of thromboembolic events. The use of diuretics, ACE inhibitors, beta-blockers, and anticoagulants is tailored to the individual patient's needs and the specific anatomical and functional abnormalities present.

Long-Term Outlook

Long-term follow-up is essential for patients with Shone's syndrome, given the risk of recurrent obstructions and the potential for progressive cardiovascular complications. Regular imaging and clinical evaluations are necessary to monitor for residual or new lesions, assess the effectiveness of previous interventions, and manage any emerging issues. The multidisciplinary care team must remain vigilant and proactive in addressing the evolving needs of these patients throughout their lifespan.

Future Directions

The future of Shone's syndrome management lies in continued advancements in surgical techniques, catheter-based interventions, and medical therapies. Emerging technologies such as three-dimensional imaging, minimally invasive surgical approaches, and novel pharmacological agents hold promise for improving outcomes. Additionally, a deeper understanding of the genetic and molecular underpinnings of Shone's syndrome may lead to targeted therapies and personalized medicine approaches, further enhancing patient care.

In conclusion, Shone's syndrome is a rare but formidable congenital heart disease requiring a sophisticated and

multifaceted approach to diagnosis and management. The integration of advanced diagnostic tools, surgical expertise, and comprehensive medical management is crucial in addressing the challenges posed by this complex condition. Through ongoing research and collaboration within the medical community, we can continue to improve the prognosis and quality of life for patients with Shone's syndrome, ultimately paving the way for better outcomes and novel therapeutic avenues.

REFERENCES

I. Shone JD, Sellers RD, Anderson RC, Adams P Jr, Lillehei CW, Edwards JE. The developmental complex of "parachute mitral valve", supravalvular ring of left atrium, subaortic stenosis, and coarctation of aorta. Am J Cardiol. 1963; 11: 714-725.

II. Roche KJ, Genieser NB, Ambrosino MM, Henry GL. MR findings in Shone's complex of left heart obstructive lesions. Pediatr Radiol. 1998; 28 (11): 841-845.

III. Brauner RA, Laks H, Drinkwater DC Jr, Scholl F, McCaffery S. Multiple left heart obstructions (Shone's anomaly) with mitral valve involvement: long-term surgical outcome. Ann Thorac Surg. 1997; 64 (3): 721-729.

IV. Ikemba CM, Eidem BW, Fraley JK, Eapen RS, Pignatelli R, Ayres NA et al. Mitral valve morphology and morbidity/mortality in Shone's complex. Am J Cardiol. 2005; 95 (4): 541-543.

V. Ma XJ, Huang GY, Liang XC, Liu XQ, Jia B. Atypical Shone's complex diagnosed by echocardiography. Pediatr Cardiol. 2011; 32 (4): 442- 448.

VI. Qamruddin S, Naqvi TZ. Advances in 3D echocardiography for mitral valve. Expert Rev Cardiovasc Ther. 2011; 9 (11): 1431-1443.

VII. Hakim FA, Kendall CB, Alharthi M, Mancina JC, Tajik JA, Mookadam F. Parachute mitral valve in adults-a systematic overview. Echocardiography. 2010; 27 (5): 581-586.

VIII. Rim Y, McPherson DD, Kim H. Effect of congenital anomalies of the papillary muscles on mitral valve function. J Med Biol Eng. 2015; 35 (1): 104-112.

IX. Brown JW, Ruzmetov M, Vijay P, Hoyer MH, Girod D, Rodefeld MD et al. Operative results and outcomes in children with Shone's anomaly. Ann Thorac Surg. 2005; 79 (4): 1358-1365.

X. Narvencar KPS, Jaques e Costa AK, Patil VR. Shone's complex. JAPI. 2009; 57: 415-416.

XI. Chandra S, Kharwar RB, Mundhekar A. Shone complex. J Cardiovasc Ultrasound. 2015; 23 (1): 54-55.

XII. Purvis JA, Smyth S, Barr SH. Multi-modality imaging of an adult parachute mitral valve. J Am Soc Echocardiogr. 2011; 24 (3): 351.e1-3.

XIII. Zucker N, Levitas A, Zalzstein E. Prenatal diagnosis of Shone's syndrome: parental counseling and clinical outcome. Ultrasound Obstet Gynecol. 2004; 24 (6): 629-632.

XIV. St Louis JD, Bannan MM, Lutin WA, Wiles HB. Surgical strategies and outcomes in patients with Shone complex: a retrospective review. Ann Thorac Surg. 2007; 84 (4): 1357-1362; discussion 1362-1363.

XV. Delmo-Walter EM, Van Praagh R, Miera O, Hetzer R. Repair of left ventricular inflow tract lesions in Shone's anomaly: valve growth and long-term outcome. Ann Thorac Surg. 2013; 95 (3): 948-955.